Targeted Disease(s):
Non-Cystic Fibrosis Bronchiectasis

Purpose of Study:

This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week Phase III study to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI).All patients who complete the 52-week double-blind treatment period on investigational product (IP) may be eligible to continue into an open-label extension (OLE), during which all patients will receive benralizumab.The OLE treatment period is intended to allow patients at least one year of treatment with open label benralizumab.

Study Dates:
July 21, 2021 - June 10, 2021

Type of Study:

Study Design:
Controlled Design

Study Location:

Funding Source:
AstraZeneca Identifier:

Name: AstraZeneca Clinical Study Information Center
Phone: 1-877-240-9479
Email: [email protected]


Trial URL:

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Freedom From Smoking Clinic
Manchester, CT | Aug 15, 2022